156 related articles for article (PubMed ID: 29603071)
1. Serum homocysteine levels are affected by renal function during a 3-year period of minodronate therapy in female osteoporotic patients.
Ohishi T; Fujita T; Suzuki D; Nishida T; Asukai M; Matsuyama Y
J Bone Miner Metab; 2019 Mar; 37(2):319-326. PubMed ID: 29603071
[TBL] [Abstract][Full Text] [Related]
2. Changes of bone mineral density and serum pentosidine during a 27-month follow-up of monthly minodronate in osteoporotic patients.
Ohishi T; Fujita T; Suzuki D; Nishida T; Yamamoto K; Okabayashi R; Ushirozako H; Banno T; Matsuyama Y
Endocr Res; 2017 Aug; 42(3):232-240. PubMed ID: 28318330
[TBL] [Abstract][Full Text] [Related]
3. The Efficacy of Minodronate in the Treatment of Glucocorticoid-induced Osteoporosis.
Hasegawa E; Ito S; Takai C; Kobayashi D; Nomura Y; Otani H; Abe A; Ishikawa H; Murasawa A; Narita I; Nakazono K
Intern Med; 2018 Aug; 57(15):2169-2178. PubMed ID: 29607978
[TBL] [Abstract][Full Text] [Related]
4. Effects of once-monthly minodronate versus risedronate in osteoporosis patients with rheumatoid arthritis: a 12-month randomized head-to-head comparison.
Kumagai K; Harigane K; Kusayama Y; Tezuka T; Choe H; Inaba Y; Saito T
Osteoporos Int; 2018 Jul; 29(7):1637-1642. PubMed ID: 29574518
[TBL] [Abstract][Full Text] [Related]
5. Initiation of Monthly Minodronate Therapy at an Early Stage After Hip Fracture.
Ohishi T; Fujita T; Suzuki D; Nishida T; Okabayashi R; Yamamoto K; Ushirozako H; Banno T; Matsuyama Y
J Clin Densitom; 2016; 19(3):352-8. PubMed ID: 27067298
[TBL] [Abstract][Full Text] [Related]
6. Patient satisfaction and efficacy of switching from weekly bisphosphonates to monthly minodronate for treatment and prevention of glucocorticoid-induced osteoporosis in Japanese patients with systemic rheumatic diseases: a randomized, clinical trial.
Tamechika SY; Sasaki K; Hayami Y; Ohmura SI; Maeda S; Iwagaitsu S; Naniwa T
Arch Osteoporos; 2018 Jun; 13(1):67. PubMed ID: 29904824
[TBL] [Abstract][Full Text] [Related]
7. Effect of osteoporosis medication on changes in bone mineral density and bone turnover markers after 24-month administration of daily teriparatide: comparison among minodronate, raloxifene, and eldecalcitol.
Nakatoh S
J Bone Miner Metab; 2018 Mar; 36(2):221-228. PubMed ID: 28293779
[TBL] [Abstract][Full Text] [Related]
8. Minodronate for the treatment of osteoporosis.
Kubo T; Shimose S; Matsuo T; Fujimori J; Ochi M
Drugs Today (Barc); 2010 Jan; 46(1):33-7. PubMed ID: 20200694
[TBL] [Abstract][Full Text] [Related]
9. Effects of intravenous zoledronic acid plus subcutaneous teriparatide [rhPTH(1-34)] in postmenopausal osteoporosis.
Cosman F; Eriksen EF; Recknor C; Miller PD; Guañabens N; Kasperk C; Papanastasiou P; Readie A; Rao H; Gasser JA; Bucci-Rechtweg C; Boonen S
J Bone Miner Res; 2011 Mar; 26(3):503-11. PubMed ID: 20814967
[TBL] [Abstract][Full Text] [Related]
10. Long-term treatment of osteoporotic women with bisphosphonates does not impair the response to subsequently administered intravenous pamidronate.
Yavropoulou MP; Hamdy NA; Papapoulos SE
Osteoporos Int; 2013 Aug; 24(8):2353-7. PubMed ID: 23436076
[TBL] [Abstract][Full Text] [Related]
11. Intravenous zoledronic acid 5 mg in the treatment of postmenopausal women with low bone density previously treated with alendronate.
McClung M; Recker R; Miller P; Fiske D; Minkoff J; Kriegman A; Zhou W; Adera M; Davis J
Bone; 2007 Jul; 41(1):122-8. PubMed ID: 17468062
[TBL] [Abstract][Full Text] [Related]
12. Randomized trial comparing efficacies of zoledronate and alendronate for improving bone mineral density and inhibiting bone remodelling in women with post-menopausal osteoporosis.
Tan W; Sun J; Zhou L; Li Y; Wu X
J Clin Pharm Ther; 2016 Oct; 41(5):519-23. PubMed ID: 27440710
[TBL] [Abstract][Full Text] [Related]
13. Effects of switching weekly alendronate or risedronate to monthly minodronate in patients with rheumatoid arthritis: a 12-month prospective study.
Ebina K; Noguchi T; Hirao M; Hashimoto J; Kaneshiro S; Yukioka M; Yoshikawa H
Osteoporos Int; 2016 Jan; 27(1):351-9. PubMed ID: 26475289
[TBL] [Abstract][Full Text] [Related]
14. Usefulness of daily teriparatide treatment in elderly patients over 80 years of age.
Niimi R; Kono T; Nishihara A; Hasegawa M; Matsumine A; Kono T; Sudo A
Osteoporos Int; 2016 May; 27(5):1869-74. PubMed ID: 26759334
[TBL] [Abstract][Full Text] [Related]
15. Effects of zoledronic acid on bone fusion in osteoporotic patients after lumbar fusion.
Chen F; Dai Z; Kang Y; Lv G; Keller ET; Jiang Y
Osteoporos Int; 2016 Apr; 27(4):1469-1476. PubMed ID: 26556733
[TBL] [Abstract][Full Text] [Related]
16. Comparison of the effects of 12 months of monthly minodronate monotherapy and monthly minodronate combination therapy with vitamin K2 or eldecalcitol in patients with primary osteoporosis.
Ebina K; Noguchi T; Hirao M; Kaneshiro S; Tsukamoto Y; Yoshikawa H
J Bone Miner Metab; 2016 May; 34(3):243-50. PubMed ID: 26303222
[TBL] [Abstract][Full Text] [Related]
17. A double-blinded head-to-head trial of minodronate and alendronate in women with postmenopausal osteoporosis.
Hagino H; Nishizawa Y; Sone T; Morii H; Taketani Y; Nakamura T; Itabashi A; Mizunuma H; Ohashi Y; Shiraki M; Minamide T; Matsumoto T
Bone; 2009 Jun; 44(6):1078-84. PubMed ID: 19264155
[TBL] [Abstract][Full Text] [Related]
18. Changes in the RANK ligand/osteoprotegerin system are correlated to changes in bone mineral density in bisphosphonate-treated osteoporotic patients.
Dobnig H; Hofbauer LC; Viereck V; Obermayer-Pietsch B; Fahrleitner-Pammer A
Osteoporos Int; 2006; 17(5):693-703. PubMed ID: 16435076
[TBL] [Abstract][Full Text] [Related]
19. Effects of denosumab on bone mineral density and bone turnover in postmenopausal women transitioning from alendronate therapy.
Kendler DL; Roux C; Benhamou CL; Brown JP; Lillestol M; Siddhanti S; Man HS; San Martin J; Bone HG
J Bone Miner Res; 2010 Jan; 25(1):72-81. PubMed ID: 19594293
[TBL] [Abstract][Full Text] [Related]
20. Minodronate combined with alfacalcidol versus alfacalcidol alone for glucocorticoid-induced osteoporosis: a multicenter, randomized, comparative study.
Soen S; Yamamoto K; Takeuchi T; Tanaka Y; Tanaka S; Ito M; Nakano T; Hagino H; Hirakawa A; Matsumoto T
J Bone Miner Metab; 2020 Jul; 38(4):511-521. PubMed ID: 31970477
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]